Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01997047
Other study ID # H12-00783
Secondary ID
Status Completed
Phase N/A
First received May 29, 2013
Last updated September 19, 2017
Start date October 2012
Est. completion date October 2014

Study information

Verified date September 2017
Source University of British Columbia
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Pneumonia is the commonest cause of death in children worldwide, killing 1.5 million children under the age of 5 years, every year. This is more than the number of children dying from AIDS, malaria and tuberculosis combined. The current diagnostic and management protocols for managing serious respiratory diseases in children are 30 years old and are greatly in need of updating. The successful establishment of useful clinical management criteria for children with respiratory diseases will have benefits for children in low resource regions around the world. The goals of the study are:

- To determine if children with respiratory distress can be reliably diagnosed under low-resource conditions.

- To identify the clinical tests that best differentiate pneumonia from wheezy diseases. These will be used to establish updated diagnostic criteria for common pediatric lung diseases that broaden the current pneumonia algorithm by adding another for wheezy illnesses.

- The ultimate objective is to improve the management and outcome of acute respiratory conditions in children.

- Investigators also wish to test the efficacy of a locally developed cell phone oximeter probe in a low resource setting.


Description:

Study organisation. This is a prospective observational study run simultaneously in four Indian public hospitals (King George Medical University, Lucknow; Regency Hospital, Kanpur; Vanivilas Hospital, Bangalore; Bowring and Lady Curzon Hospital, Bangalore). The study started in Oct 2012 to cover the Indian respiratory viral season. In order to maintain high standards of data collection, a post-graduate research coordinator is employed at each hospital. Because of the use of standardised scoring systems and the need for accurate clinical data collection, a member from the Canadian team spent a week at each centre familiarising local research team members with the study protocol and standardised scoring systems. This was followed by a one week trial period of data collection and electronic transmission of files to Canada.

Diagnostic definitions and standardised scores. The primary problem facing any study of pneumonia is accurate diagnosis. The overlap of clinical and radiological findings between severe viral infections, asthma and bacterial pneumonia can make it difficult to determine which febrile tachypneic children have wheezy diseases and which ones would benefit from antibiotic treatment. In many low-resource areas, this is further complicated by infectious diseases, such as malaria and dengue, which can have similar presentations. Early WHO tachypnea-based diagnostic protocols were intentionally over-sensitive to ensure that all children with bacterial pneumonia received antibiotics. Later attempts were made to improve the detection of wheezy diseases, by adding audible wheeze or acute bronchodilator response to the basic criteria. However, these were shown to be imprecise, particularly amongst the sickest children.

Investigators chose to formalize the diagnostic method described by Sachdev et al who classified patients into four groups (pneumonia, wheezy disease, mixed and non-respiratory) based on consultant review of a detailed history and examination plus a chest radiograph (CXR). Investigators recorded 29 items from a protocol that included history, examination, CXR and oximetry (see table). In order to combine results from data collection between centres, standardised scoring systems for conscious level and auscultation findings were used. For chest radiographs, a modification of the recently updated system recommended by the WHO was used. During the one week preparatory period, the system was explained to all involved ER physicians and pediatricians using examples and practice interpretation.

Study protocol. All children below 5 years age who present to the emergency rooms of the study hospitals with cough or difficulty breathing of less than 5 days, are identified. If their initial respiratory rate met WHO criteria for pneumonia, the study is explained by a native speaker of their primary language and they are invited to enter the study. Families are not paid to enrol but the study covers the cost of a CXR for every child plus travel expenses for outpatients to return for review on day four. After enrolment, twenty nine features of the child's history, examination and CXR are assessed by the ER physician and recorded by the study coordinator(Table 2).

After reviewing the data, the ER physician is asked to place the child into one of four diagnostic categories: pneumonia, wheezy disease (asthma and bronchiolitis), mixed (evidence of pneumonia and wheeze) and non-respiratory (malaria, dengue etc). The ER physician is solely responsible for subsequent management decisions. All study patients are reviewed four days later by a qualified pediatrician who is blinded to the ER physician's CXR interpretation and diagnosis. Based on a review of the clinical data at presentation, plus subsequent course over 4 days and a second examination, the pediatrician places the patient into one of the four diagnostic categories. This is considered the child's final diagnosis for analysis.

Statistical analysis. Logistic regression analysis will be used to determine which of the initial clinical variables had the best predictive power for pneumonia and asthma. The best cut-off values for continuous variables were established using receiver operating curve analysis. For each predictive variable, sensitivity, specificity plus positive and negative predictive value will be calculated from conventional tables using standard equations. When the predictive value of combining variables is tested, investigators will link them as 'A and/or B'. This increases sensitivity but decreases specificity, compared to using 'A and B.' Continuous variables will be displayed as mean +/- one standard deviation. Categorical variables will be displayed with box and whisker plots where the whiskers represent full range.

Table of investigations performed in the ER at presentation.

History Recorded details Cough yes/no Difficulty Breathing yes/no Lethargy yes/no Reduced feeding yes/no Fever yes/no Previous similar episodes number Vaccinations number and type

Examination Recorded details Age months Weight weight for age 'z' score Temperature ⁰ Celsius Heart rate beats/minute Respiratory rate breaths/minute Indrawing present/absent

Responsiveness score:

A fully alert V responds to voice P responds to pain U unconscious

Auscultation score:

Chest clear normal vesicular breath sounds Crackles coarse or fine inspiratory crackles/rattles Wheeze high pitched whistling noise, inspiratory or expiratory Crackles and wheeze both sounds present Bronchial breathing tracheal breath sounds heard over the lungs

Investigations Recorded details

CXR score: one or more of:

Normal ) Hyperinflation ) Minor patchy changes ) definitions, see table 3 Major patchy changes ) Lobar changes ) Pleural fluid ) Oximetry % oxygen saturation


Recruitment information / eligibility

Status Completed
Enrollment 502
Est. completion date October 2014
Est. primary completion date April 2014
Accepts healthy volunteers No
Gender All
Age group N/A to 5 Years
Eligibility Inclusion Criteria:

- All children below 5 exceeding WHO age-dependent tachypnea criteria.

Exclusion Criteria:

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Canada BC's Children's Hospital Vancouver British Columbia

Sponsors (1)

Lead Sponsor Collaborator
University of British Columbia

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Other Child's oxygen saturation measured by cell-phone oximeter and bedside Massimo commercial oximeter The anesthetic department has developed a smart phone application that allows saturation readings to be made with an attachable finger probe. These readings will be compared to a those measured using a standard commercial oximeter. one year
Primary Child's diagnosis in one of four categories (pneumonia, wheezy disease, mixed and non-respiratory) All children enrolled in the study, fulfill WHO criteria for pneumonia on day one. After assessing 29 different variables at presentation (day 1), including CXR, oximetry, pulse, respiratory rate, a qualified pediatrician makes the primary study diagnosis on day 4. Based on the results and review of progress, the consultant places the child into one of four diagnostic groups - pneumonia, wheezy disease, mixed and non-respiratory. These are the principal reference diagnoses for the rest of the analyses. One year
Secondary Child's clinical outcome in three categories (better, worse, dead) After diagnostic review on day 4, the child's clinical outcome is also noted. The child is placed into three outcome categories - better, worse, dead. One year
See also
  Status Clinical Trial Phase
Completed NCT04624425 - Additional Effects of Segmental Breathing In Asthma N/A
Terminated NCT04410523 - Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma Phase 2
Active, not recruiting NCT03927820 - A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR) N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT03694158 - Investigating Dupilumab's Effect in Asthma by Genotype Phase 4
Terminated NCT04946318 - Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma Phase 2
Completed NCT04450108 - Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients N/A
Completed NCT03086460 - A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH) Phase 2
Completed NCT01160224 - Oral GW766944 (Oral CCR3 Antagonist) Phase 2
Completed NCT03186209 - Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE) Phase 3
Completed NCT02502734 - Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma Phase 3
Completed NCT01715844 - L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics Phase 1
Terminated NCT04993443 - First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036 Phase 1
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT06033833 - Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study Phase 2
Completed NCT03257995 - Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma. Phase 2
Completed NCT02212483 - Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients N/A
Recruiting NCT04872309 - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Withdrawn NCT01468805 - Childhood Asthma Reduction Study N/A
Recruiting NCT05145894 - Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device